New drug advances have the potential to solve some of society’s most pressing health issues, but forecasting a drug’s effectiveness can sometimes feel like a shot in the dark. That lack of knowledge often leads investors to back clinical-trial-stage companies with big ambitions that don’t pan out.
Steve Truong WG21, Dave Latshaw II WG21, and Dan Sciubba WG21 are helping investors make more informed decisions with proprietary artificial-intelligence technology designed to better predict trial successes. Through its own investing arm, BioPhy is pursuing better returns for its backers and more optimal outcomes for patients.
Read more from the Watchlist.
